IDVYNSO DIN 02568748
Health Canada record
| Active ingredient(s) | DORAVIRINE 100 MG; ISLATRAVIR 0.25 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AG NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INH |
| Original market date | |
| Current status date | 03-Jun-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DORAVIRINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02482592 | DELSTRIGO | MERCK CANADA INC | Tablet | DORAVIRINE 100 MG; LAMIVUDINE 300 MG; TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02481545 | PIFELTRO | MERCK CANADA INC | Tablet | DORAVIRINE 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37657 | 2026-06-03 | New Drug Submission (NDS) |
International API supply for DORAVIRINE
2 active FDA Drug Master Files.
Request a quote for IDVYNSO